FDA panel vote on olodaterol positive for Theravance drug, says Piper Jaffray Piper Jaffray believes the positive FDA panel recommendation for Boehringer's olodaterol in COPD signals a similar outcome for Theravance's Breo's panel on March 7. The firm recommends buying shares of Theravance ahead of the FDA panel and keeps an Overweight rating on the name with a $32 price target.
News For THRX From The Last 14 Days
Check below for free stories on THRX the last two weeks.
Theravance, GlaxoSmithKline receive Australian approval for Breo Ellipta GlaxoSmithKline (GSK) and Theravance (THRX) announced that the Therapeutic Goods Administration has approved BREO ELLIPTA for the treatment of patients with asthma or chronic obstructive pulmonary disease, or COPD, in Australia. Two strengths of BREO ELLIPTA have been licensed for the treatment of asthma and one strength has been licensed for the treatment of COPD.